European-based company MyCartis developed its proprietary Dynamic Multi-Analyte Technology (DMAT®). DMAT® is an advanced and unique technology to deliver superior data quality and rapid results for analyzing multiple protein and nucleic acid-based biomarkers. To close the gap between the user requirements of their target groups and its unique technology, MyCartis invited Invetech to develop a solution around its technology that would be tailored to the clinical research and pharmaceutical markets.
The result of this partnership is the Evalution®, a multiplex diagnostic platform that provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay. The core technology surrounds the imaging and fluorescence reading of 40-micron binary-coded silicon microparticles.
Thousands of different digital codes can be generated and the platform provides fast and highly sensitive detection of a broad range of biomarkers. The flexibility and simplicity of the workflow enables researchers to streamline procedures for biomarker verification and validation, and to accelerate the translation of novel content to clinical practice.